newsfilter
← Latest News
Business Wire·

AVROBIO Reports Third Quarter 2022 Financial Results and Provides Business Update

Patient dosing completed in collaborator-sponsored Phase 1/2 clinical trial for cystinosis Rare pediatric disease designations received for Gaucher disease and cystinosis investigational gene therapies Comprehensive